Santos, Fabio P S <br/><br/>
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.  [electronic resource] 

 -  Blood  Feb 2010 
 - 1131-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2009-10-246363  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Blotting, Western<br/>Carbazoles--therapeutic use<br/>Cytokines--metabolism<br/>Female<br/>Furans<br/>Humans<br/>Janus Kinase 2--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Polycythemia Vera--complications<br/>Primary Myelofibrosis--complications<br/>Prognosis<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Survival Rate<br/>Thrombocythemia, Essential--complications<br/>Treatment Outcome